Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Shionogi Inc. Announces Commercial Availability of KAPVAYâ„¢ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD

January 10, 2011 By Bio-Medicine.Org

FLORHAM PARK, N.J., Jan. 10, 2011 /PRNewswire/ — Shionogi Inc.,
the U.S.-based group company of Shionogi & Co., Ltd., today
announced a true milestone as it marks the first commercial
availability for the non-central nervous system stimulant
medication KAPVAY™, an extended-release oral formulation of
clonidine for Attention Deficit Hyperactivity Disorder (ADHD) in
children and adolescents.  KAPVAY™ is the first and only
FDA-approved ADHD treatment indicated for use as add-on therapy to
stimulant medication, in addition to use as monotherapy.

“Shionogi is extremely proud to bring KAPVAY™ to market in
the U.S.,” said Donald C. Manning, MD, PhD, Chief Medical Officer
of Shionogi Inc.  “The extended-release version of clonidine
hydrochloride found in KAPVAY™ offers an exciting new
treatment option for children and adolescents with ADHD who are not
experiencing adequate symptom relief from stimulants alone.”
 

ADHD affects more than 4.5 million children in the U.S., with at
least 7 percent of U.S. school-aged children believed to suffer
from the condition.  Symptoms include difficulty in
maintaining attention and focus and in controlling behavior, as
well as hyperactivity/over-activity.  While stimulant
medications remain a first line treatment for ADHD, up to 30
percent of ADHD patients do not achieve an optimal response to
stimulant monotherapy.

KAPVAY™’s recent FDA approval was based on two Phase III
studies, which demonstrated significant efficacy at Week 5 in
children and adolescents (6-17 years) with ADHD treated with
KAPVAY™.  Signs and symptoms of ADHD were evaluated
using the investigator administered and scored ADHD Rating
Scale-IV-Parent Version (ADHDRS-IV) total score, including
hyperactive/impulsivity and inattentive subscales.
 Treatment-emergent adverse events, such as somnolence and
fatigue, were mostly mild to moderate. Thirteen percent (13%) of
patients

‘/>”/>

SOURCE

Related Articles Read More >

Blackrock's Utah array is a miniature array of electrodes for sensing brain signals
Blackrock Neurotech and Pitt work on first at-home BCI system for remote trials
DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation

DeviceTalks Weekly.

July 1, 2022
Boston Scientific CEO Mike Mahoney on building a corporate culture that drives high growth results
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech